The CEACAM5 drugs market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer and the increasing number of CEACAM5 that are under clinical trials. Currently, there are no CEACAM5 approved by any regulatory bodies.
LAS VEGAS , Sept. 17, 2024 /PRNewswire/ -- DelveInsight's CEACAM5 Drugs Market Insights report includes a comprehensive understanding of current treatment practices, emerging CEACAM5 drugs, market share of individual therapies, and current and forecasted CEACAM5 drugs market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ), the United Kingdom , and Japan ]. Key Takeaways from the CEACAM5 Market Report As per DelveInsight's analysis, the total market size of CEACAM5 drugs in the 7MM is expected to surge significantly by 2034.
Leading CEACAM5 drug companies such as SurgiMab, Merck KGaA, Sanofi, Hoffmann-La Roche, and others are developing novel CEACAM5 drugs that can be available in the CEACAM5 drugs market in the coming years. Some of the key CEACAM5 drugs in the pipeline include SGM-101, M9140, SGN-CEACAM5C, Cibisatamab + RO7122290 , and others. In June 2024 , Merck KGaA shared preliminary data from a Phase I study of M9140 , a novel antibody-drug conjugate (ADC) targeting CEACAM5, at the American Society of Clinical Oncology (ASCO) Annual Meeting.
This trial included 40 patients with advanced colorectal cancer who had previ.